Amova Asset Management Americas Inc. Decreases Stake in Adaptive Biotechnologies Corporation $ADPT

Amova Asset Management Americas Inc. lowered its holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 15.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,650,646 shares of the company’s stock after selling 649,038 shares during the quarter. Amova Asset Management Americas Inc. owned 2.39% of Adaptive Biotechnologies worth $54,650,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. XTX Topco Ltd purchased a new position in Adaptive Biotechnologies in the second quarter valued at about $793,000. SG Americas Securities LLC boosted its stake in shares of Adaptive Biotechnologies by 53.2% during the 2nd quarter. SG Americas Securities LLC now owns 37,328 shares of the company’s stock worth $435,000 after acquiring an additional 12,963 shares in the last quarter. Hillsdale Investment Management Inc. acquired a new stake in shares of Adaptive Biotechnologies in the 2nd quarter worth approximately $6,618,000. Allianz Asset Management GmbH grew its holdings in shares of Adaptive Biotechnologies by 305.8% in the 3rd quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock worth $4,814,000 after acquiring an additional 242,474 shares during the period. Finally, Envestnet Asset Management Inc. purchased a new position in Adaptive Biotechnologies in the 2nd quarter valued at approximately $467,000. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Adaptive Biotechnologies Trading Up 2.2%

Adaptive Biotechnologies stock opened at $16.44 on Thursday. The stock has a fifty day moving average price of $16.85 and a 200 day moving average price of $15.79. Adaptive Biotechnologies Corporation has a 52 week low of $6.26 and a 52 week high of $20.76. The firm has a market capitalization of $2.53 billion, a P/E ratio of -41.10 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. During the same quarter last year, the firm posted ($0.23) earnings per share. Adaptive Biotechnologies’s revenue was up 51.0% on a year-over-year basis. As a group, equities analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Insider Transactions at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 289,024 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $15.82, for a total transaction of $4,572,359.68. Following the completion of the sale, the chief executive officer owned 1,987,330 shares of the company’s stock, valued at approximately $31,439,560.60. The trade was a 12.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert Hershberg sold 22,968 shares of the firm’s stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $16.00, for a total value of $367,488.00. Following the completion of the transaction, the director owned 46,722 shares in the company, valued at approximately $747,552. This trade represents a 32.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,082,417 shares of company stock worth $17,725,999 over the last ninety days. 6.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

ADPT has been the subject of a number of research analyst reports. TD Cowen restated a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Morgan Stanley assumed coverage on shares of Adaptive Biotechnologies in a report on Monday, December 1st. They set an “equal weight” rating and a $21.00 target price for the company. JPMorgan Chase & Co. upped their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Friday, February 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Finally, Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a research report on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $18.25.

More Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Company reported a quarterly earnings beat with strong revenue growth (revenue up ~51% YoY), which underpins the stock’s positive momentum. MarketBeat ADPT summary
• Positive Sentiment: Several sell-side firms raised price targets or reiterated Buy/Overweight ratings (Guggenheim, JPMorgan, Piper Sandler, Wall Street Zen), giving investors analyst support for higher valuations. Analyst coverage summary
• Neutral Sentiment: Reported short-interest entries show 0 shares (days-to-cover 0.0) — this appears to be a data error or non-material and shouldn’t be interpreted as meaningful short activity. (No actionable link.)
• Neutral Sentiment: Small institutional activity: several funds reported modest new or increased positions in the fourth quarter; institutional ownership remains high (~99%), so movements are incremental. MarketBeat ownership note
• Negative Sentiment: CEO Chad Robins executed multiple large sales in late Feb–early Mar (including 53,083 shares on Mar 3 and larger blocks on Mar 2 and Feb 27), reducing his stake materially; large insider sales can create short-term selling pressure or raise governance/insider-confidence questions. Chad Robins sale alert
• Negative Sentiment: Director/insider Harlan S. Robins also sold smaller blocks (10,000 and 14,233 shares on Mar 2–3), further increasing headline insider selling volume. Harlan S. Robins filings

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.